The agonizing itching is one of the most difficult symptoms to bear in patients with primary biliary cholangitis (PBC). It can have a far greater impact on everyday life, sleep and mental stability than the laboratory values of the underlying disease. New studies and congress papers from 2025 show that the therapeutic spectrum has expanded significantly in recent years. The focus today is on the targeted modulation of cholestatic mechanisms, in particular through inhibitors of bile acid transport and PPAR agonists, which not only have a favorable effect on the course of the disease but also on the symptom burden.
Autoren
- Tanja Schliebe
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Case study
Wiedemann-Steiner syndrome in a 2-year-old girl
- Chronic back pain
Care in the virtual hospital – the Back@home project
- Psoriatic arthritis
Long-term remission also possible without DMARDs
- Clinical relevance, benefits and limitations
Atrial Fibrillation Screening
- Parkinson's disease: progressive and clinically heterogeneous
Individualized management of motor and non-motor symptoms
- Type 2 diabetes and heart failure: a bidirectional relationship
Proactive preventive measures can reduce the burden of disease
- Dementia
Delirium risks and treatment strategies
- Colorectal cancer screening